AstraZeneca, GSK pipeline cuts Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 29 April, 2026

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

presented by Glob­al part­ner­ing be­fore the term sheet: de-risk­ing bio­phar­ma deals from day one

news MPM has collected three China drugs so far for its ‘best of both worlds’ strategy AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts

Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher May 20 11:00 am ET Application of Simple Western to analysis of antibody target affinity and specificity sponsored by Bio-Techne

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

ENDPOINTS PHARMA The Supreme Court will determine how a fish oil pill shakes up the generics market FDA announces real-time clinical trial data effort, with AstraZeneca and Amgen as test cases Pfizer delays patent cliff for blockbuster heart drug Updated: FDA claims trial 'manipulation' tainted approval of ChemoCentryx drug now owned by Amgen Novartis CEO disheartened by Germany’s planned €60B cuts to healthcare spending

in case you missed it 1. Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel 2. Lilly strikes second partnership this year for recombinase-based gene editing 3. BeOne joins the VEGF competition, but with a trispecific antibody 4. Incyte claims double Phase 3 win in vitiligo, will file for approval 5. Galapagos spinout Coultreon raises $125M for new take on SIK inhibition 6. Boehringer, Zealand’s obesity shot looks as good as Wegovy but weaker than Zepbound